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Comparative Chemotherapeutic Efficacy in Non-small Cell
Lung Cancer Patients with Postoperative Recurrence and
Stage IV Disease
Ikuo Sekine, MD, PhD, Hiroshi Nokihara, MD, PhD, Noboru Yamamoto, MD, PhD,
Hideo Kunitoh, MD, PhD, Yuichiro Ohe, MD, PhD, and Tomohide Tamura, MD
Background: Whether chemotherapy would be equally effective in
non-small cell lung cancer patients with stage IV disease (group A)
and postoperative recurrence (group B) remains unclear.
Patients and Methods: In a total of 642 non-small cell lung cancer
patients with distant metastases treated by chemotherapy, the base-
line patient characteristics, responses to chemotherapy and survival
were compared between group A (n  480) and group B (n  162).
Results: Adenocarcinoma was the predominant histologic type,
accounting for 78% of the patients in group A and 90% of the
patients in group B (p  0.001). Bone and brain metastases were
more common in group A (p  0.034 and p  0.014, respectively),
although pulmonary metastases were more common in group B (p
0.001). The chemotherapy regimens used for the treatment did not
differ between groups A and B. The response rates in group A and
group B were 32 and 33%, respectively (p  0.65). In contrast, the
median progression-free survival (5.5 versus 4.2 months, p 
0.0065) and overall survival (21.3 versus 13.3 months, p  0.001)
were better in group B than in group A.
Conclusion: Survival was superior in patients with postoperative
recurrence than in those with stage IV disease, although the two
groups showed comparable responses to chemotherapy.
Key Words: Chemotherapy, Non-small cell lung cancer, Postoper-
ative recurrence, Stage IV disease.
(J Thorac Oncol. 2009;4: 518–521)
Until now, non-small cell lung cancer (NSCLC) patientsshowing disease recurrence after surgery for the primary
lesion have been treated with systemic chemotherapy or
supportive care alone, in accordance with the treatment of-
fered for patients with stage IV disease,1 although there have
been no comparative studies specifically conducted on these
patients. Furthermore, clinical trials conducted to evaluate the
efficacy of chemotherapy have, in most cases, included pa-
tients with postoperative recurrence as well as those with
stage IV disease. However, whether chemotherapy would be
equally effective in the two groups of patients remains un-
clear. The objectives of this retrospective study were to
compare the patient characteristics, responses to chemother-
apy, and survival between these two patient groups.
PATIENTS AND METHODS
Patient Selection
Patients were retrospectively selected for this study
according to the following criteria (1): a histologic or cyto-
logic diagnosis of NSCLC (2); presence of distant metastases
at the time of the initial diagnosis (stage IV disease) or
postoperative recurrence (3); no prior chemotherapy; and (4)
received chemotherapy at the National Cancer Center Hos-
pital between December 2000 and June 2006. Patients were
excluded if they had only postoperative local recurrence
without distant metastases. All patients underwent systematic
evaluation and standardized staging procedures before the
start of systemic treatment. Clinical stage was assigned based
on the results of physical examination, chest radiography,
computed tomography scans of the chest and abdomen,
computed tomography or magnetic resonance imaging of the
brain, and bone scintigraphy. The histologic classification of
the tumor was based on the criteria of the World Health
Organization.2
Data Collection and Statistical Analyses
Patients’ baseline characteristics, including age, sex,
performance status, histology, site of distant metastases,
number of distant metastases, and chemotherapy regimens
were obtained retrospectively from the medical charts. Mea-
surable lesions and objective tumor responses were defined
according to Response Evaluation Criteria in Solid Tumors
(RECIST).3 All pretreatment and treatment parameters were
compared between the two groups, that is, the group with
stage IV disease (group A) and the group with postoperative
recurrence (group B). 2 and Mann-Whitney tests were used
to evaluate the differences in categorical and continuous
variables, respectively, between the two groups. The overall
and progression-free survivals were evaluated using the
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Kaplan-Meier method and logrank test. Cox proportional
hazards models were used to adjust for potential confounding
factors.4 All analyses were performed using the Dr. SPSS II
11.0 for Windows software (SPSS Japan Inc., Tokyo, Japan).
RESULTS
Patient Characteristics
A total of 642 patients met the eligibility criteria for this
study. Of these, 480 patients (75%) had stage IV disease
(group A) and 162 (25%) had postoperative recurrence
(group B). In group B, pathologic stage I, stage II, stage III,
and stage IV disease was noted in 49 (30%), 32 (20%), 76
(47%), and 5 (3%) patients, respectively. The median interval
from the day of the operation for the primary disease and the
first day of chemotherapy was 22.2 months. Baseline char-
acteristics stratified by the groups are summarized in Table 1.
Sex distribution did not differ between the two groups, but
the median age was 2.5 years higher in group B. Adenocar-
cinoma was the predominant histologic type, accounting for
78% of patients in group A and 90% of patients in group B
(p  0.001). The predominant sites of metastases differed
between the two groups; bone and brain metastases were
more common in group A (p  0.034 and p  0.014,
respectively), although pulmonary metastases were more
common in group B (p  0.001). Chemotherapy regimens
used for first-line chemotherapy did not differ between the
two groups. Platinum-based chemotherapy, nonplatinum dou-
blet chemotherapy, mono-chemotherapy with a third-genera-
tion cytotoxic agent, and epidermal growth factor receptor
tyrosine kinase inhibitors were administered in 360 (75%), 4
(1%), 29 (6%), and 87 (18%) patients in group A, respec-
tively, and 109 (67%), 5 (3%), 18 (11%), and 30 (19%)
patients in group B, respectively.
Responses and Survival
A total of 472 (98%) of the 480 patients in group A, but
only 100 (62%) of the 162 patients in group B, had measur-
able lesions (p  0.001, Table 2). Among patients with
measurable lesions, responses to chemotherapy were compa-
rable between the patients of group A and group B (Table 2).
Progression-free survival, however, was superior in group B
FIGURE 1. Progression-free survival in patients with stage
IV disease (open square, n  480) and in those with postop-
erative recurrence (open circle, n  162).
TABLE 2. Objective Responses to Chemotherapy
Group A Group B
n (%) n (%) p
Measurable lesions (n  642) 0.001
Yes 472 (98.3) 100 (61.7)
No 8 (1.7) 62 (38.3)




Complete response 5 (1.1) 1 (1.0)
Partial response 145 (30.7) 32 (32.0)
Stable disease 170 (36.0) 29 (29.0)
Progressive disease 100 (21.2) 23 (23.0)
Not evaluablea 52 (11.0) 15 (15.0)
a In these patients, chemotherapy was discontinued early because of toxicity. Group
A: patients with stage IV disease; group B: patients with postoperative recurrence.





n (%) n (%) p
Sex 0.23
Female 173 (36.0) 67 (41.4)
Male 307 (64.0) 95 (58.6)
Age median (range) 60 (24–86) 62.5 (32–81) 0.004
Histology 0.001
Adenocarcinoma 375 (78.1) 145 (89.5)
Nonadenocarcinoma 105 (21.9) 17 (10.5)
Performance status 0.23
0 137 (28.5) 60 (37.0)
1 316 (65.8) 95 (58.6)
2 22 (4.6) 6 (3.7)
3 5 (1.0) 4 (0.6)
No. of metastatic organs 0.96
1 303 (63.1) 104 (64.2)
2 125 (26.0) 39 (24.1)
3 35 (7.3) 13 (8.0)
4–6 17 (3.5) 6 (3.7)
Metastatic sites
Bone 0.034
No 287 (59.8) 112 (69.1)
Yes 193 (40.2) 50 (30.9)
Brain 0.014
No 347 (72.3) 133 (82.1)
Yes 133 (27.7) 29 (17.9)
Lung 0.001
No 256 (53.3) 57 (35.2)
Yes 224 (46.7) 105 (64.8)
Liver 0.26
No 423 (88.1) 148 (91.4)
Yes 57 (11.9) 14 (8.6)
a Group A: patients with stage IV disease; group B: patients with postoperative
recurrence.
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than in group A (5.5 versus 4.2 months, p  0.0065, Figure 1).
Overall survival was also superior in group B than in group
A (21.3 versus 13.3 months, p  0.001, Figure 2). The
interval between the day of operation and the first day of
chemotherapy had a significant impact on the survival from
the start of chemotherapy. Median survival time (MST) from
the start of chemotherapy was 23.6 and 27.8 months, respec-
tively, in patients in whom the interval was 15.0 to 29.9
months and 30 months or longer, respectively. In contrast, the
median survival time from the start of chemotherapy was
only 11.7 months in the patients in whom the interval was
less than 15.0 months (p  0.001), which was comparable
with that in patients with stage IV disease (group A; 13.4
months) (Figure 3). Pathologic stage at the time of surgery
had no impact on the overall survival of the patients in group
B. Other known prognostic factors including male sex, a poor
performance status, a large number of metastatic organs, and
the presence of bone metastasis were associated with poor
patient survival (Table 3), whereas brain metastasis had no
impact on survival (hazard ratio, 1.11; 95% confidence inter-
val, 0.91–1.35; p  0.30) and pulmonary metastasis was
associated with a better survival (Table 3). Multivariate
analysis using a Cox’s proportional hazard model showed
that patients in group B had a better prognosis than those in
group A with a hazard ratio of 0.66 (95% confidence interval,
0.54–0.81, p  0.001) (Table 3).
DISCUSSION
This study revealed different characteristics of patients
with postoperative recurrence who received systemic chemo-
therapy for tumor recurrence in comparison with those of
patients with stage IV disease among NSCLC patients. Con-
sidering the interval between the operation and chemother-
apy, the median value of which was 22 months, it is under-
standable that the median age of patients with postoperative
recurrence was 2 years higher than that of the patients with
stage IV disease. The percentage of patients with adenocar-
cinoma was higher in the group of patients with postoperative
recurrence, probably because recurrence after surgical resec-
tion may be more common in patients with adenocarcinoma
than in patients with squamous cell carcinoma. This is con-
sistent with a previous report that squamous cell histology
was associated with a good prognosis among patients with
stage IIIA disease.5 Recent large-scale randomized trials in
previously treated advanced NSCLC patients have shown that
epidermal growth factor receptor tyrosine kinase inhibitors
are more effective against adenocarcinomas (with response
rates of 12–13%) than against nonadenocarcinomas (with
response rates of no more than 5%).6,7 In the current study,
these agents were administered as a first-line chemotherapy in
FIGURE 2. Overall survival in patients with stage IV disease
(open square, n  480) and in those with postoperative re-
currence (open circle, n  162).
FIGURE 3. Overall survival in patients with stage IV disease
(open square, n  480) and in those with postoperative recur-
rence according to the interval between the day of the opera-
tion and the first day of chemotherapy. The interval had a sig-
nificant impact on the survival from the start of chemotherapy.
Open circle (n  54), interval of 30.0 months or longer; open
triangle (n  53), interval of 15.0 to 29.9 months, and closed
circle (n  55), interval shorter than 15.0 months.









Male 1.56 (1.30–1.86) 0.001 1.58 (1.32–1.90)
Performance status
0 1 1
1 1.43 (1.19–1.74) 0.001 1.31 (1.08–1.58) 0.007
2–3 2.76 (1.88–4.05) 0.001 2.49 (1.67–3.70) 0.001
Number of metastatic
organsa
1.25 (1.13–1.37) 0.001 1.26 (1.12–1.42) 0.001
Bone metastasis 0.91
No 1 1
Yes 1.45 (1.22–1.73) 0.001 1.01 (0.82–1.25)
Pulmonary metastasis 0.005
No 1 1
Yes 0.72 (0.61–0.85) 0.001 0.76 (0.63–0.92)
Group 0.001
A 1 1
B 0.63 (0.51–0.77) 0.001 0.66 (0.54–0.81)
a With an increment of one. Group A: patients with stage IV disease; group B:
patients with postoperative recurrence.
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18% of the patients with stage IV disease and in 19% of the
patients with postoperative recurrence; no data regarding the
use of these agents in second-line or subsequent chemother-
apy regimens was available. Thus, the use of this class of
agents may have influenced the survival difference between
the patients with stage IV disease and those with postopera-
tive recurrence. Brain and bone metastases were significantly
less common in patients with postoperative recurrence in this
study. These patients may have been less frequently referred
to medical oncologists, possibly because of a poor perfor-
mance status and could therefore be suitable candidates for
palliative radiotherapy. However, pulmonary metastases were
significantly more common in the group with postoperative
recurrence, possibly because these patients can only be
treated with systemic chemotherapy.
Thirty-eight percent of patients with postoperative re-
currence had no measurable lesions. Many of these patients
had multiple small pulmonary metastases, but no evidence of
recurrence at other sites. Excluding these patients, evaluation
of the response to chemotherapy revealed no difference in
percentages of patients showing complete and partial re-
sponses between the two groups. Thus, it is reasonable to
include patients with postoperative recurrence in studies in
which the primary end point is the response rate, such as
conventional phase II studies, as long as they have measur-
able disease.
Patient survival was significantly superior in patients
with postoperative recurrence compared with those with stage
IV disease in this study, with a hazard ratio of 0.66 (p 
0.001). To our knowledge, there are no such data in the
medical literature except one report, which showed that prior
lung surgery may have been associated with a better progno-
sis, with a hazard ratio of 0.86.8 This reported difference,
however, was much smaller than that found in this study.
Patients with postoperative recurrence constitute a heteroge-
neous group, and patients with a relatively better prognosis
tended to be included in this group in the current study. The
disease-free interval between the operation and recurrence
has been reported as a prognostic factor.9 In this study,
patients with an interval from the operation to the start of
postrecurrence chemotherapy of less than 15.0 months had a
survival rate as poor as that in patients with stage IV disease.
These patients who showed relatively early recurrence ac-
counted for only one-third of all the patients with postoper-
ative recurrence in this study. In conclusion, the NSCLC
patients with postoperative recurrence had characteristics
different from those with stage IV disease in this study, but
the two groups showed comparable responses to chemother-
apy. Survival, both progression-free and overall, was superior
in those with postoperative recurrence as compared with
those with stage IV disease, especially those having a post-
operative disease-free interval of more than 15 months.
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